Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Gene Technique Targets Alzheimer’s Memory Loss
Uncategorized

Gene Technique Targets Alzheimer’s Memory Loss

By medwebJan 1, 2004
Share
Facebook Twitter Email

Gene Technique Targets Alzheimer’s Memory Loss

Feinberg School of Medicine researchers have prevented learning and memory deficits in a model of Alzheimer’s disease using a gene-targeting approach to block production of beta-amyloid, or “senile” plaques, one of the hallmarks of the disease.

Alzheimer’s disease is a neurodegenerative condition affecting more than 15 million people worldwide that causes memory loss and, ultimately, dementia. Some research suggests that Alzheimer’s disease is caused by an increased amyloid burden in the brain—the so-called amyloid cascade hypothesis.

Results of the Northwestern study, published in the January issue of the journal Neuron, provide compelling evidence for the therapeutic potential of inhibiting an enzyme, beta-secretase (BACE1), required for the production of beta-amyloid, to treat memory impairment in patients with Alzheimer’s disease.

The study also presents new evidence that beta-amyloid is directly responsible for causing the memory-robbing effects of Alzheimer’s disease, said Masuo Ohno, PhD, research assistant professor of physiology at the medical school.

Dr. Ohno’s co-researchers on the project were John F. Disterhoft, PhD, professor of physiology, and Robert J. Vassar, PhD, associate professor of cell and molecular biology.

Dr. Ohno and colleagues used behavioral, biochemical, and electrophysiologic methods to analyze BACE1 in mice bred to lack the enzyme but to also overproduce amyloid precursor protein, which BACE1 “clips” into fragments of beta-amyloid that eventually form the notorious plaques associated with Alzheimer’s disease.

The mice were healthy and had no serious neurological abnormalities, suggesting that BACE1 inhibition is a rational strategy for treating Alzheimer’s disease, Dr. Ohno said.

Importantly, the beneficial effects of BACE1 inhibition in the mice were seen well before beta-amyloid plaques formed, indicating that the soluble forms of the protein can disrupt learning and memory in early stages of the disease process.

“Potential compounds that block BACE1 should be useful in counteracting the Alzheimer’s disease process,” Dr. Ohno said. “We clearly show for the first time that genetic reduction of brain beta-amyloid levels prevents memory deficits and brain cell functional abnormalities in a laboratory model of Alzheimer’s disease.”

“This well-executed study in mice is another step forward toward demonstrating the validity of anti-amyloid interventions in Alzheimer’s disease. The next step is to see if this works in more sophisticated models of the disease, and eventually in humans. ” said William Thies, vice president of medical and scientific affairs for the Alzheimer’s Association, which funded part of the study.

The National Institutes of Health also funded the study.

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023

Northwestern Simulation’s In Situ Training Tests Cardiac Arrest Response Teams

Sep 25, 2023

Investigating the Link Between Iron Deficiency and Regulation of Cell Growth

Sep 25, 2023

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.